Research
Pharmacological Trials
Casa di Cura Igea has started the following pharmacological studies
ADVANCE
International Phase 3 study funded by the pharmaceutical company Baxalta, to evaluate the efficacy, safety and tolerability of a subcutaneous immunoglobulin infusion for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
– study in progress
EMBARK (Aducanumab)
“A Phase 3b, open-label, multicenter safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302, and 221AD205.”
This pharmacological experimentation is financed by the company "Biogen", which uses the CRO IQVIA RDS Italy srl
– study concluded
PROMISE (Protein Misfolding)
Multicenter (IRCCS Besta) randomized phase II pharmacological study with futility design for amyotrophic lateral sclerosis and guanabenz.
– study concluded
ENGAGED
international multicenter Phase 3 study funded by the pharmaceutical company BIOGEN, to evaluate the efficacy and safety of an innovative drug, called Aducanumab, aimed at the treatment of subjects affected by early Alzheimer's disease.
– study concluded
CREATE
international multicenter randomized double-blind Phase 3 study funded by the pharmaceutical company ROCHE, to evaluate the efficacy and safety of Crenezumab in patients with mild forms of Alzheimer's disease (probable AD / prodromal AD).
– study concluded
MS-COG
multicenter study funded by the pharmaceutical company BIOGEN on healthy subjects, aimed at establishing the reference values for the MS-COG cognitive assessment scale in a population comparable to that of patients affected by Multiple Sclerosis.
– study concluded
GRADUATE
Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety study to evaluate the efficacy and safety of gantenerumab in patients with early (prodromal to mild) Alzheimer's disease.
– study concluded
